Scoliosis

OrthoPediatrics Corp. Reports Fourth Quarter and Full Year 2023 Financial Results

Retrieved on: 
Wednesday, March 6, 2024

Total revenue for the fourth quarter of 2023 was $37.6 million, a 21% increase compared to $31.0 million for the same period last year.

Key Points: 
  • Total revenue for the fourth quarter of 2023 was $37.6 million, a 21% increase compared to $31.0 million for the same period last year.
  • The increase in revenue in the fourth quarter of 2023 was driven primarily by growth across Trauma and Deformity, Scoliosis, and OPSB.
  • In the fourth quarter of 2023, we realized an immaterial fair value adjustment benefit compared to a $0.5 million benefit for the fourth quarter of 2022.
  • Adjusted EBITDA for the fourth quarter of 2023 was $1.3 million as compared to a loss of $2.2 million for the fourth quarter of 2022.

OrthoPediatrics Corp. Launches New RESPONSE Rib and Pelvic Fixation System for EOS Scoliosis

Retrieved on: 
Monday, March 4, 2024

WARSAW, Ind., March 04, 2024 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS a company focused exclusively on advancing the field of pediatric orthopedics, today announced it has launched a new RESPONSE™ Rib and Pelvic Fixation system to treat children with Early Onset Scoliosis (“EOS”).

Key Points: 
  • WARSAW, Ind., March 04, 2024 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS a company focused exclusively on advancing the field of pediatric orthopedics, today announced it has launched a new RESPONSE™ Rib and Pelvic Fixation system to treat children with Early Onset Scoliosis (“EOS”).
  • The new addition to the RESPONSE™ family includes implants and instruments for rib and pelvic fixation, and associated devices to connect the fixation points.
  • As an adjunct to the foundational RESPONSE™ Scoliosis System, the Rib and Pelvic system is compatible with 5.5/6.0 and 4.5/5.0 RESPONSE™ Systems, allowing surgeons to treat the entire spectrum of patients with scoliosis.
  • Greg Odle, President of the OrthoPediatrics’ Scoliosis Division echoed his excitement for the launch of this new system, saying “We are excited to enter the Early Onset Scoliosis treatment market with the RESPONSE™ Rib & Pelvic System.

HSS Orthopedics with Stamford Health Establishes Premier Spine Center in Connecticut

Retrieved on: 
Monday, February 26, 2024

STAMFORD, Conn., Feb. 26, 2024 /PRNewswire/ -- Back pain is a complex, widespread issue across the United States, with the Centers for Disease Control and Prevention estimating that 65 million Americans are affected. Common reasons include arthritis, disc and nerve injury, muscle strain, and other underlying health conditions such as osteoporosis and scoliosis. Responding to the urgent need for increased access to high quality spine care in Connecticut, a specialist center was created last year as an extension of the collaboration between Hospital for Special Surgery (HSS) and Stamford Health.

Key Points: 
  • Responding to the urgent need for increased access to high quality spine care in Connecticut, a specialist center was created last year as an extension of the collaboration between Hospital for Special Surgery (HSS) and Stamford Health.
  • The HSS Spine Center with Stamford Health led by co-medical directors Steven J. McAnany, MD , spine surgeon at HSS, and Andrea F. Douglas, MD, FAANS, FACS , chief of Neurosurgery at Stamford Health, builds on a successful collaboration started in 2016.
  • "The HSS Spine Center with Stamford Health harnesses the expertise of our respective institutions to bring world-class patient care to the communities we serve," said Kathleen Silard, president and CEO at Stamford Health.
  • "Over the past year, hundreds of patients with back and neck conditions have benefitted from the exceptional capabilities and proven expertise we offer through the HSS Spine Center with Stamford Health."

Momentum Health receives FDA 510K Clearance for Momentum Spine, a Pioneering AI-Enabled Mobile Application for Monitoring Scoliosis, Available for Download Now!

Retrieved on: 
Thursday, February 15, 2024

After receiving their Health Canada class 1 medical device clearance, Momentum Spine continues to gain traction with FDA clearance and the launch of their mobile app.

Key Points: 
  • After receiving their Health Canada class 1 medical device clearance, Momentum Spine continues to gain traction with FDA clearance and the launch of their mobile app.
  • MONTREAL, Feb. 15, 2024 /CNW/ - Momentum Health Inc. is excited to announce that its innovative mobile application, Momentum Spine, has received U.S. Food and Drug Administration (FDA) clearance.
  • With the recent FDA clearance, Momentum Health is progressing to the commercialization phase for the Momentum Spine technology.
  • Dr. Jean Ouellet, a Pediatric Spine Surgeon and the Chief Medical Officer of Momentum Health Inc., shared his enthusiasm: "Receiving FDA clearance is a monumental achievement for Momentum Health.

New York youth honored as Prudential Emerging Visionaries

Retrieved on: 
Tuesday, February 13, 2024

NEWARK, N.J., Feb. 13, 2024 /PRNewswire/ -- Sunya Afrasiabi, 17, of Buffalo, and OlaRose Ndubuisi, 16, of Pittsford, today were each named a 2024 Prudential Emerging Visionary for their inspiring commitment to improving the lives of others.

Key Points: 
  • Prudential Emerging Visionaries recognizes young people ages 14-18 whose fresh perspectives and innovative solutions address pressing financial and societal challenges in their communities.
  • Prudential Emerging Visionaries is sponsored by Prudential in collaboration with Ashoka, a leading organization in the social impact sector, with advisory support provided by the Financial Health Network, an authority on financial health and a longtime partner of The Prudential Foundation.
  • The program is an evolution of Prudential's Spirit of Community Awards, which honored more than 150,000 outstanding youth volunteers over 26 years.
  • To read about all of this year's Prudential Emerging Visionaries, visit prudential.com/emergingvisionaries .

Prudential Financial introduces its next class of Emerging Visionaries

Retrieved on: 
Tuesday, February 13, 2024

NEWARK, N.J., Feb. 13, 2024 /PRNewswire/ -- Twenty-five young leaders from across the U.S. have been honored by Prudential Financial today as the latest class of Prudential Emerging Visionaries.

Key Points: 
  • NEWARK, N.J., Feb. 13, 2024 /PRNewswire/ -- Twenty-five young leaders from across the U.S. have been honored by Prudential Financial today as the latest class of Prudential Emerging Visionaries.
  • Prudential Emerging Visionaries honors exceptional students ages 14-18 who have created innovative, bold solutions to financial and societal challenges in their communities.
  • Prudential Emerging Visionaries is sponsored by Prudential in collaboration with Ashoka, a leading organization in the social impact sector, with advisory support provided by the Financial Health Network, an authority on financial health and a longtime partner of The Prudential Foundation.
  • For more information about Prudential Emerging Visionaries and to learn more about their stories, visit prudential.com/emergingvisionaries .

Biogen Received European Commission Approval for SKYCLARYS® (omaveloxolone), the First Therapy to Treat Friedreich’s Ataxia

Retrieved on: 
Monday, February 12, 2024

“Friedreich’s ataxia patients treated with SKYCLARYS in the clinical trial experienced important and clinically meaningful improvements for their daily lives.

Key Points: 
  • “Friedreich’s ataxia patients treated with SKYCLARYS in the clinical trial experienced important and clinically meaningful improvements for their daily lives.
  • At the end of the 48-week study, patients who received SKYCLARYS had significantly improved modified Friedreich Ataxia Rating Scale (mFARS) scores relative to placebo.
  • Biogen is committed to working closely with all stakeholders to ensure that eligible European patients can have access to this treatment.
  • SKYCLARYS is also approved for use in the United States, and Biogen is engaging with regulatory authorities in other regions.

Introducing 'Breathe mE': The Pioneering Hypopressive Breathing Program by Nanda Semenyuk, the First US Certified Hypopressive Coach

Retrieved on: 
Tuesday, January 23, 2024

This groundbreaking program is designed to cater to a wide audience, unraveling the science behind hypopressive breathing and its multitude of benefits, such as enhancing pelvic floor strength, improving posture, and boosting respiratory health.

Key Points: 
  • This groundbreaking program is designed to cater to a wide audience, unraveling the science behind hypopressive breathing and its multitude of benefits, such as enhancing pelvic floor strength, improving posture, and boosting respiratory health.
  • Nanda's journey to becoming the first US certified hypopressive coach is rooted in her personal triumph over postpartum recovery challenges and scoliosis.
  • Her remarkable transformation through hypopressive breathing led her to obtain certification and pioneer this method in the US.
  • For additional details and enrollment, visit BreathemE.Coach
    Contact: Nanda Semenyuk, Breathe mE Coach with YU2SHINE, http://breatheme.coach/

The Orthopedic Partners Expands Services to Include Pediatric Services

Retrieved on: 
Tuesday, January 16, 2024

PARK CITY, Utah, Jan. 16, 2024 /PRNewswire/ -- The Orthopedic Partners (TOP), a leading orthopedic care provider based in Utah, announced the expansion of its services to include pediatric orthopedic care with the addition of John Heflin, M.D., John Smith, M.D. and Marcella Woiczik, M.D., to its team of esteemed orthopedic physicians.

Key Points: 
  • PARK CITY, Utah, Jan. 16, 2024 /PRNewswire/ -- The Orthopedic Partners (TOP), a leading orthopedic care provider based in Utah, announced the expansion of its services to include pediatric orthopedic care with the addition of John Heflin , M.D., John Smith, M.D.
  • The pediatric team at TOP has earned national and international recognition for each physician's diverse experience in treating children ranging from ages 0-18 and for their contributions to research and education.
  • "We are thrilled to join The Orthopedic Partners, building on its outstanding reputation in delivering exceptional care to treat orthopedic injuries, in addition to acute and chronic disorders," said Dr. Woiczik.
  • TOP's pediatric team also provides surgical care at Primary Children's Hospital and Intermountain Park City Hospital.

OrthoPediatrics Corp. Announces Acquisition of Boston Orthotics & Prosthetics

Retrieved on: 
Monday, January 8, 2024

WARSAW, Ind., Jan. 08, 2024 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced that it has acquired Boston Orthotics & Prosthetics (“Boston O&P”), a leader in pediatric orthotic management for over 50 years. Additionally, in advance of the acquisition, the Company closed a debt financing with MidCap Financial which provides up to $80 million of capital, through the combination of a term loan and revolving loan, replacing its prior unused $50 million line of credit.

Key Points: 
  • WARSAW, Ind., Jan. 08, 2024 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced that it has acquired Boston Orthotics & Prosthetics (“Boston O&P”), a leader in pediatric orthotic management for over 50 years.
  • Boston Orthotics & Prosthetics is a profitable company offering leading bracing, orthotic and prosthetic technology for the non-operative treatment of children whose lives have been impacted by scoliosis, plagiocephaly, and various neuromuscular disorders.
  • In advance of the acquisition, OrthoPediatrics entered into a new credit agreement with MidCap Financial, consisting of term loan and revolving loan.
  • In advance of the acquisition, OrthoPediatrics drew an initial $10 million from the term loan.